Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

Published:2024-07 Issue: Volume: Page:
ISSN:2531-1379
Container-title:Hematology, Transfusion and Cell Therapy
language:en
Short-container-title:Hematology, Transfusion and Cell Therapy

Author:

Vráblová Lucia,Klamová Hana,Skoumalová Ivana,Navrátilová Jana,Janská Romana,Grohmann Jan,Holzerová Milena,Faber Edgar^ORCID

Funder

Ministry of Health of the Czech Republic

Palacky University Olomouc

Publisher

Elsevier BV

Reference29 articles.

1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia;Hochhaus;Leukemia,2020

2. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034;Shah;Am J Hematol,2016

3. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial;Hochhaus;Leukemia,2016

4. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial;Cortes;J Clin Oncol,2018

5. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial;Cortes;Blood,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP